ReviewRenal failure2025
Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection.Indian journal of pharmacology · 2026Review
- Elevated angiography-derived microvascular resistance and HbA1c levels jointly predict adverse outcomes in patients with diabetic STEMI: a multicenter retrospective cohort study.Frontiers in endocrinology · 2026Observational
- Protocol for a Prospective, Multicenter Cohort Study on the Treatment of Chronic Cardiorenal Syndrome with Qishen Yiqi Dropping Pills.Clinical pharmacology : advances and applications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesChronic cardiorenal syndrome (types 2 and 4) arises from chronic dysfunction of either the heart or kidneys, leading to progressive deterioration of the other organ. The coexistence of cardiac and renal dysfunction significantly complicates treatment strategies and is associated with high morbidity and mortality, with currently limited effective therapeutic options. Given the demonstrated cardiorenal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i), it is important to explore their potential mechanisms and clinical application value in the treatment of non-diabetic chronic cardiorenal syndrome.
methodsThis review systematically analyzes the multiple mechanisms of SGLT2i and integrates the latest clinical trial evidence to evaluate their potential application in the management of non-diabetic chronic cardiorenal syndrome. It specifically examines their cardiorenal protective pathways beyond glucose-lowering effects, including diuretic and natriuretic actions, improved hemodynamics, inhibition of neurohormonal overactivation, modulation of inflammation and oxidative stress, and enhancement of vascular endothelial function.
resultsRecent clinical studies confirm that SGLT2i exert cardiorenal protection through multiple mechanisms and demonstrate potential for improving prognosis in non-diabetic patients with cardiorenal syndrome. Combination therapy with mineralocorticoid receptor antagonists and glucagon-like peptide-1 receptor agonists shows synergistic therapeutic advantages.
conclusionsSGLT2i provide a novel therapeutic strategy for chronic cardiorenal syndrome, with their multi-target mechanisms offering new perspectives for combined cardiorenal protection. However, further clinical research is required to optimize treatment protocols and address practical challenges in their application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.